Skyrizi (risankizumab) - AbbVie, Boehringer Ingelheim
Skyrizi: Initiation of P3 trial for ulcerative colitis in 2020 (AbbVie) - Feb 8, 2020 - Pipeline Update: Initiation of P3 trial for atopic dermatitis in 2021 
New P3 trial
https://investors.abbvie.com/static-files/0f2e0201-ef33-432c-904e-8cf78d2d0929
 
Feb 8, 2020
 
 
169a9be0-fad4-4b38-a866-9923a7a2f2c6.jpg